Evaluation of 18F-Fluciclovine Positron Emission Tomography – Magnetic Resonance Imaging (PET-MRI) in LGG

Participation Deadline: 09/01/2027
Apply Now

Description

The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.